Cargando…
CXCL5: A coachman to drive cancer progression
Chemokines are a class of pro-inflammatory cytokines that can recruit and activate chemotactic cells. C‐X‐C motif chemokine ligand 5 (CXCL5) is a member of the chemokine family binding CXCR2 (C-X-C Motif Chemokine Receptor 2), a G-protein coupled receptor. Accumulated evidence has shown that dysregu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376318/ https://www.ncbi.nlm.nih.gov/pubmed/35978824 http://dx.doi.org/10.3389/fonc.2022.944494 |
_version_ | 1784768140983402496 |
---|---|
author | Deng, Jie Jiang, Rongqi Meng, Enqing Wu, Hao |
author_facet | Deng, Jie Jiang, Rongqi Meng, Enqing Wu, Hao |
author_sort | Deng, Jie |
collection | PubMed |
description | Chemokines are a class of pro-inflammatory cytokines that can recruit and activate chemotactic cells. C‐X‐C motif chemokine ligand 5 (CXCL5) is a member of the chemokine family binding CXCR2 (C-X-C Motif Chemokine Receptor 2), a G-protein coupled receptor. Accumulated evidence has shown that dysregulated CXCL5 participates in tumor metastasis and angiogenesis in human malignant tumors. In this review, we summarized the advances in research on CXCL5, including its dysregulation in different tumors and the mechanism associated with tumor behavior (formation of the immunosuppressive microenvironment, promotion of tumor angiogenesis, and metastasis). We also summarized and discussed the perspective about the potential application of CXCL5 in tumor therapy targeting the tumor inflammatory microenvironment. |
format | Online Article Text |
id | pubmed-9376318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93763182022-08-16 CXCL5: A coachman to drive cancer progression Deng, Jie Jiang, Rongqi Meng, Enqing Wu, Hao Front Oncol Oncology Chemokines are a class of pro-inflammatory cytokines that can recruit and activate chemotactic cells. C‐X‐C motif chemokine ligand 5 (CXCL5) is a member of the chemokine family binding CXCR2 (C-X-C Motif Chemokine Receptor 2), a G-protein coupled receptor. Accumulated evidence has shown that dysregulated CXCL5 participates in tumor metastasis and angiogenesis in human malignant tumors. In this review, we summarized the advances in research on CXCL5, including its dysregulation in different tumors and the mechanism associated with tumor behavior (formation of the immunosuppressive microenvironment, promotion of tumor angiogenesis, and metastasis). We also summarized and discussed the perspective about the potential application of CXCL5 in tumor therapy targeting the tumor inflammatory microenvironment. Frontiers Media S.A. 2022-08-01 /pmc/articles/PMC9376318/ /pubmed/35978824 http://dx.doi.org/10.3389/fonc.2022.944494 Text en Copyright © 2022 Deng, Jiang, Meng and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Deng, Jie Jiang, Rongqi Meng, Enqing Wu, Hao CXCL5: A coachman to drive cancer progression |
title | CXCL5: A coachman to drive cancer progression |
title_full | CXCL5: A coachman to drive cancer progression |
title_fullStr | CXCL5: A coachman to drive cancer progression |
title_full_unstemmed | CXCL5: A coachman to drive cancer progression |
title_short | CXCL5: A coachman to drive cancer progression |
title_sort | cxcl5: a coachman to drive cancer progression |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376318/ https://www.ncbi.nlm.nih.gov/pubmed/35978824 http://dx.doi.org/10.3389/fonc.2022.944494 |
work_keys_str_mv | AT dengjie cxcl5acoachmantodrivecancerprogression AT jiangrongqi cxcl5acoachmantodrivecancerprogression AT mengenqing cxcl5acoachmantodrivecancerprogression AT wuhao cxcl5acoachmantodrivecancerprogression |